The progress of novel androgen receptor inhibitors for non-metastatic castration-resistant prostate cancer
10.3760/cma.j.cn112330-20210408-00002
- VernacularTitle:非转移性去势抵抗性前列腺癌抗雄药物治疗新进展
- Author:
Yonghong LI
1
;
Dong CHEN
;
Fangjian ZHOU
Author Information
1. 中山大学肿瘤防治中心泌尿外科，广州 510060
- Keywords:
Prostatic neoplasms;
Non-metastatic;
Castration-resistant;
Novel androgen receptor inhibitors;
Apalutamide;
Enzalutamide;
Darolutamide
- From:
Chinese Journal of Urology
2021;42(Z1):6-9
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is one of the most common cancers threatening the health of males. The incidence of prostate cancer in China is on the rise. Non-metastatic castration-resistant stage is a special disease stage during the progression of prostate cancer, early identification of nmCRPC and prompt intervention can help delay disease progression and prolong patient survival. In recent years, many studies demonstrated the efficacy of novel androgen receptor inhibitors such as apalutamide, in prolonging metastasis-free survival and time to symptomatic progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). This article reviews the recent progress of novel androgen receptor inhibitors for nmCRPC.
